The FDA recorded approval of a supplemental application for Zepbound (tirzepatide) on August 26, 2026. The application, identified as NDA 217806 S-41, was classified by the agency as an efficacy submission and was sponsored by Eli Lilly and Company.
Background
Tirzepatide is listed in the supplied FDA record under the brand names Zepbound and Zepbound KwikPen, as well as Mounjaro and Mounjaro KwikPen. The event concerns Zepbound and an efficacy-related supplemental application. The available data do not provide a mechanism of action, dosing information, disease prevalence figures, or details of prior indications.
What this means
The event establishes that the FDA approved the supplemental application associated with NDA 217806 S-41. The record classifies the submission as “Efficacy,” indicating that the application concerned efficacy information. However, the supplied data do not identify a new indication, patient population, endpoint, study, comparator, treatment effect, safety finding, or label language.
Because those details were not included, this record alone does not establish what clinical-use change resulted from the supplemental approval or how efficacy compared with another treatment or placebo. Clinicians, researchers, patient advocates, and editors should consult the FDA application record for the underlying regulatory details before drawing conclusions about use of tirzepatide.
Source
Source: U.S. Food and Drug Administration, Center for Drug Evaluation and Research application overview for NDA 217806, reflecting the supplemental efficacy approval dated August 26, 2026. The record is available at accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA217806.